Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. by Whilding, LM et al.
CorrectionTargeting of Aberrant avb6 Integrin Expression
in Solid Tumors Using Chimeric Antigen
Receptor-Engineered T Cells
Lynsey M. Whilding, Ana C. Parente-Pereira, Tomasz Zabinski, David M. Davies, Roseanna M.G. Petrovic,
Y. Vincent Kao, Shobhit A. Saxena, Alex Romain, Jose A. Costa-Guerra, Shelia Violette, Hiroaki Itamochi,
Sadaf Ghaem-Maghami, Sabari Vallath, John F. Marshall, and John Maher
Correspondence: john.maher@kcl.ac.uk (J.M.)
http://dx.doi.org/10.1016/j.ymthe.2017.09.018
(Molecular Therapy 25, 259–273; January 4, 2017)
The authors regret that King’s Health Partners Confidence in Concept was inadvertently omitted as a funding source in the Acknowledgments
section of the original paper. The corrected Acknowledgments section appears below and has been corrected online. We apologize for any
inconvenience this may have caused.ACKNOWLEDGMENTS
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